Browsing Clinical Studies by author "Chau, Ian"
Now showing items 1-14 of 14
-
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Fendler, A; Shepherd, STC; Au, L; Wilkinson, KA; Wu, M; et al. (NATURE PORTFOLIO, 2021-10-27) -
Beyond genomics - Targeting the epigenome in diffuse large B-cell lymphoma.
Kühnl, A; Cunningham, D; Chau, I (2017-09)After decades of intense research on genetic alterations in cancer and successful implementation of genetically-based targeted therapies, the field of cancer epigenetics is only beginning to be fully recognized. The discovery ... -
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Athauda, A; Watkins, D; Mohammed, K; Chau, I; Starling, N; et al. (2018-10)Background/aim Cisplatin-based radical chemoradiotherapy (CRT) is utilised in oesophagogastric (OG) cancer but the toxicity profile of cisplatin limits its use. This study aimed to evaluate the clinical characteristics and ... -
Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
Sclafani, F; Brown, G; Cunningham, D; Wotherspoon, A; Mendes, LST; et al. (2017-11)Background Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer.Methods mrTRG and pTRG were compared in rectal cancer patients from two phase ... -
Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?
Smyth, EC; Tarazona, N; Peckitt, C; Armstrong, E; Mansukhani, S; et al. (2016-06)Background Strict eligibility criteria are necessary to maintain patient safety and scientific validity in clinical trials. However, this may lead to impaired generalizability of results. As survival in gastrointestinal ... -
Genomic loss of heterozygosity and survival in the REAL3 trial.
Smyth, EC; Cafferkey, C; Loehr, A; Waddell, T; Begum, R; et al. (2018-11-30)Background Homologous recombination deficiency (HRD) measured using a genomic signature for loss of heterozygosity (LOH) predicts benefit from rucaparib in ovarian cancer. We hypothesized that some oesophagogastric cancers ... -
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancer.
Davidson, M; Chau, I; Cunningham, D; Khabra, K; Iveson, T; et al. (2017-08)Aim To investigate the impact of histology on outcome in advanced oesophageal cancer treated with first-line fluoropyrimidine-based chemotherapy.Methods Individual patient data were pooled from three randomised phase III ... -
Molecular profiling of colorectal pulmonary metastases and primary tumours: implications for targeted treatment.
Moorcraft, SY; Jones, T; Walker, BA; Ladas, G; Kalaitzaki, E; et al. (2017-09)This study aimed to molecularly characterise colorectal pulmonary metastases (PM) and investigate whether their molecular profiles were concordant with those of the primary tumour. Clinical data and archival formalin fixed ... -
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani, F; Brown, G; Cunningham, D; Wotherspoon, A; Tait, D; et al. (2016-08)Background EXPERT and EXPERT-C were phase II clinical trials of neoadjuvant chemotherapy (NACT) followed by chemoradiotherapy (CRT) in high-risk, locally advanced rectal cancer (LARC).Design We pooled individual patient ... -
Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials.
Athauda, A; Nankivell, M; Langer, R; Pritchard, S; Langley, RE; et al. (SPRINGERNATURE, 2023-06-15)BACKGROUND: No definitive largescale data exist evaluating the role of pathologically defined regression changes within the primary tumour and lymph nodes (LN) of resected oesophagogastric (OG) adenocarcinoma following ... -
Platinum-Fluoropyrimidine and Paclitaxel-Based Chemotherapy in the Treatment of Advanced Anal Cancer Patients.
Sclafani, F; Morano, F; Cunningham, D; Baratelli, C; Kalaitzaki, E; et al. (2017-04)Background Although treatment of localized anal cancer (AC) is well established, very little evidence is available to inform the management of advanced tumors, and the prognosis of these patients remains poor. We have ... -
SARS-CoV-2 Vaccine Immunogenicity in Patients with Gastrointestinal Cancer Receiving Systemic Anti-Cancer Therapy.
Lau, DK; Aresu, M; Planche, T; Tran, A; Lazaro-Alcausi, R; et al. (OXFORD UNIV PRESS, 2022-11-07)INTRODUCTION: Patients with gastrointestinal (GI) cancers have an increased risk of serious complications and death from SARS-CoV-2 infection. The immunogenicity of vaccines in patients with GI cancers receiving anti-cancer ... -
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani, F; Brown, G; Cunningham, D; Rao, S; Tekkis, P; et al. (2017-06)Background The potential of chemotherapy as salvage treatment after failure of neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC) has never been explored. We conducted a single-center, retrospective ... -
Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
Khan, K; Cunningham, D; Chau, I (2017-01)Colorectal cancer (CRC) is one of the commonest cancers in the world. During the last decade, the development of targeted therapies has given cancer treatment a novel direction in management of metastatic CRC (mCRC) and ...